Stock Comparison

ABBV vs TERN

AbbVie Inc vs Terns Pharmaceuticals Inc

Who's the better investment? Let's break it down.

The Verdict

Dead heat.

Both stocks scored 0.1/10. You'll need to dig deeper into the qualitative factors to pick a winner here.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

TERN

Terns Pharmaceuticals Inc

0.1

out of 10

Distressed

Want to compare any two stocks?

Valuation

ABBV

Metric

TERN

$381.1B

Market Cap

$6.1B

104.8

P/E Ratio

Lower may indicate better value

-51.4

14.4

Forward P/E

N/A

51.1

Price/Book

N/A

Profitability & Growth

ABBV

Metric

TERN

5.8%

Profit Margin

N/A

72.0%

Gross Margin

N/A

24.4%

Operating Margin

N/A

95.6%

Return on Equity

-20.0%

2.7%

Return on Assets

-19.4%

9.5%

Revenue Growth

-100.0%

$2.05

EPS

$-1.03

Financial Health

ABBV

Metric

TERN

20.2

Debt-to-Equity

Lower = less leverage

0.1

0.7

Current Ratio

Above 1.0 is healthy

62.4

0.3

Beta

Lower = less volatile

-0.4

3.2%

Dividend Yield

None

Risk Comparison

ABBV

Overall

Moderate

Financial

Low

Market

Low

Competitive

High

Execution

Medium

Regulatory

High

What Could Go Wrong

AbbVie's future growth relies heavily on the continued success and market share expansion of its next-generation immunology drugs, Skyrizi and Rinvoq, which together are projected to reach over $32 bi...

Red Flags

🚩Insider Selling Activity: 4 insider sales and 0 purchases in the last 6 months, as per the Quiver so...
🚩High R&D Investment for Uncertain Returns: While inherent to pharma, the substantial R&D expenditure...
🚩GAAP EPS Volatility: The Q1 2026 GAAP diluted EPS of $0.39, a -45.8% YoY decline due to an unfavorab...

TERN

Overall

Not Applicable

Financial

Not Applicable

Market

Not Applicable

Competitive

Not Applicable

Execution

Not Applicable

Regulatory

Not Applicable

What Could Go Wrong

For former shareholders, the only remaining 'risk' would have been if the Merck acquisition (announced in March 2026) had failed to close by May 5, 2026. However, the deal completed as planned, and Te...

Red Flags

🚩Company delisted on May 5, 2026.
🚩No longer trades publicly.
🚩All shareholder equity converted to cash at $53.00/share.

Competitive Moat

ABBV

Rating

🛡️ Wide

Trend

➡️ Stable

Intangible Assets/IPSwitching CostsBrand PowerCost Advantages (via scale in R&D and manufacturing)

TERN

Rating

🛡️ None

Trend

➡️ Not Applicable

Investment Thesis

ABBV0.1/10

If AbbVie's key immunology drugs, Skyrizi and Rinvoq, continue to expand their market share globally and achieve their projected combined annual revenue of over $32 billion by 2027, complemented by successful advancements in its neuroscience and oncology pipelines, then the company will sustain mid-to-high single-digit revenue growth and generate substantial free cash flow, supporting its robust d...

Full ABBV Analysis

TERN0.1/10

The investment thesis for Terns Pharmaceuticals as a high-risk, high-reward 10x growth opportunity is entirely negated. The company was acquired by Merck for $53.00 per share and subsequently delisted on May 5, 2026. All independent growth potential has been capitalized and transferred to Merck. Terns no longer represents a viable investment for public equity investors.

Full TERN Analysis

Price Targets & Strategy

Price Targets & Entry/Exit Strategy

Growth Catalysts

Growth Catalysts Comparison

Market Sentiment

Market Sentiment Analysis

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the mature, highly regulated nature of the pharmaceutical industry inherently preclude the possibility of ...

Full ABBV Analysis

TERN0.1/10

Score Change Explanation: The score has been maintained at an extremely low level (0/100, down from the previous 1/100) to reflect the definitive and irreversible change in Terns Pharmaceuticals' status. On May 5, 2026, Merck completed its acquisition of TERN for $53.00 per share, and the company has since been delisted from Nasdaq. This corporate action entirely eliminates TERN's independent existence as a public company and, consequently, any possibility of it generating 10x growth for public ...

Full TERN Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →View Top 100 →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.